 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C13H21N3O |
| Molar mass | 235.331 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
PF-592,379 is a drug developed by Pfizer which acts as a potent, selective and orally active agonist for the dopamine D3 receptor, which is under development as a potential medication for the treatment of female sexual dysfunction and male erectile dysfunction. Unlike some other less selective D3 agonists, a research study showed that PF-592,379 has little abuse potential in animal studies, and so was selected for further development and potentially human clinical trials.[1][2] Development has since been discontinued.[3]
See also
References
- ^ Attkins N, Betts A, Hepworth D, Heatherington AC (November 2010). "Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 40 (11): 730–42. doi:10.3109/00498254.2010.514961. PMID 20836725. S2CID 30288414.
- ^ Collins GT, Butler P, Wayman C, Ratcliffe S, Gupta P, Oberhofer G, Caine SB (June 2012). "Lack of abuse potential in a highly selective dopamine D3 agonist, PF-592,379, in drug self-administration and drug discrimination in rats". Behavioural Pharmacology. 23 (3): 280–91. doi:10.1097/FBP.0b013e3283536d21. PMC 3365486. PMID 22470105.
- ^ "Drug Profile: PF 592379". Adis Insight. Springer Nature Switzerland AG.
This page was last edited on 31 January 2024, at 22:41